Medical Writing Good Pharma Providing value for medicines in older people
mew-150pxjpg

Volume 22, Issue 4 - Good Pharma

Providing value for medicines in older people

Abstract

The global population is ageing, but inequalities remain in older people's access to treatment, especially people 75 years of age and older. These people receive less frequent interventions and lower quality medical treatment than their younger counterparts. Explanations for these inequalities include ageism, a lack of testing of medicines in older people, unclear diagnoses resulting in hesitancy to institute treatment, polypharmacy, and a general lack of concordance and compliance. In Europe, responsibility for improving this situation lies with the pharmaceutical industry, the European Medicines Agency, national regulatory agencies, prescribers, dispensing pharmacists, and the patients or consumers themselves. Clinical trial and health economic data are needed to assure the effective and safe treatment of older people.

Download the full article

References

  1. United Nations Department of Economic and Social Affairs Population Division. World Population Ageing 1950–2050. ST/ESA/SER.A/207. New York, 2001.
  2. Marmot M, Allen J, Bell R, Bloomer E, Goldblatt P. Consortium for the European Review of Social Determinants of Health and the Health Divide. Lancet. 2012;380(9846):1011–29.
  3. Swedish National Board of Health and Welfare. Drug treatment in elderly care. Report from national thematic supervision of activities. Stockholm: Swedish National Board of Health and Welfare; 2004. Swedish.
  4. Larkin M. Robert Butler: championing a healthy view of ageing. Lancet. 2001;357(9249):48.
  5. Commission of the European Communities. Proposal for a Council Directive on implementing the principle of equal treatment between persons irrespective of religion or belief, disability, age or sexual orientation. Brussels: Commission of the European Communities; 2008. COM(2008)426 final.
  6. Council of the European Union. Regulation (EC) No 1901/2006 of the European parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. Off J Eur Union 2006;L 378/1.
  7. European Medicines Agency. EMA geriatric medicines strategy. EMA/CHMP/137793/2011. London: Council of the European Union; 2011. EMA/CHMP/137793/2011.
  8. Boëthius G, Westerholm B. How much can we determine about consumption of psychotropic drugs? Läkartidningen 1979;76(46):4101–4102. Swedish.
  9. de Almeida A, Aslani P. Medicines concordance in clinical practice. Br J Clin Pharmacol 2008;66(4):453–454.
  10. Swedish National Board of Health and Welfare. Public comparisons 2013: drug treatments. Stockholm: Swedish National Board of Health and Welfare; 2013. Swedish.
  11. Swedish National Board of Health and Welfare. Indications for good drug treatment in older persons. Stockholm: Swedish National Board of Health and Welfare; 2010. Swedish.
  12. O'Mahony D. Medication errors: older patients & their caregivers. Presentation at the European Union Regulatory Workshop on Medication Errors; London; 28 February–1 March 2013 [cited 2013 September 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/03/WC500139866.pdf
  13. European Medicines Agency. Tackling medication errors: European Medicines Agency workshop calls for coordinated EU approach [press release]. London: European Medicines Agency; 2013.
  14. Council of the European Union. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance. Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union 2010;L348/84.

Search

Articles

Good pharma
Message from the President
Transparency and the healthcare industry: The Sun is shining
Sunshine spreading across the Atlantic and over Europe
Bad karma
If a misinformed voice speaks out in the wilderness and no one refutes it, does it make a sound? A call to advocacy
The Big Pharma conspiracy theory
Editorial: Pharmaism
Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles
A decade of change: A new ISMPP has arrived
Selling evidence over the counter: Do community pharmacists engage with evidence-based medicine?
Good regulatory practice and the role(s) of a regulatory affairs professional
Profile: An interview with Dr Gustavo A. Silva on the concept of public health in medical writing and translation
AuthorAID: An international service and chance to serve
India as a hub for ethical and evidence-based medical communications
Providing value for medicines in older people
In the Bookstores
Journal Watch
The Webscout
Regulatory Writing
Medical Communications
Manuscript Writing
Out On Our Own
Erratum
The Light Stuff

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

  • Victoria White (Tampa, Florida, USA) Email: MEW@emwa.org
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: